HYPD:NASDAQ, Hyperion DeFi Inc Com (New)

Why HYPD stock rose on October 29

Hyperion DeFi Inc Com (New) rose 16.8% on Thursday, October 29, 2026, on 544,100 shares. No headline about HYPD came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

HYPD stock overview

Hyperion DeFi Inc Com (New) (HYPD:NASDAQ) closed at $3.07 on November 4, 2026, up 0.66% on the day. The stock trades 52.6% below its 52-week high of $6.48 and 31.2% above its 52-week low of $2.34. Over the past year, it lost 45.9%. Hyperion DeFi Inc Com (New) is part of the Health Care sector.

Key figures

Price
$3.07
Day change
+0.66%
Volume
99,753
Average volume
457,350
Market cap
46M+
52-week range
$2.34 – $6.48
50-day average
$3.42
200-day average
$3.36

Price action over the past year

In 252 trading sessions since November 4, 2025, HYPD closed higher on 118 days (47%). Its best day was December 19, 2025 (+22.33%) and its worst was May 6, 2026 (-22.06%). The stock moved 10% or more in a single session 29 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

HYPD news

About Hyperion DeFi Inc Com (New)

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

Similar stocks

Find more stocks like HYPD with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.